Related references
Note: Only part of the references are listed.The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy
Anais Hagege et al.
THERANOSTICS (2021)
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Maximilian Ackermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo
Xingkang He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
Renaud Grepin et al.
THERANOSTICS (2020)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte et al.
CELL (2019)
Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors
Annelies Verbiest et al.
CLINICAL GENITOURINARY CANCER (2018)
Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting
Annelies Verbiest et al.
CLINICAL GENITOURINARY CANCER (2018)
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
Maeva Dufies et al.
THERANOSTICS (2018)
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
Maeva Dufies et al.
BRITISH JOURNAL OF CANCER (2017)
Evidence for Pro-angiogenic Functions of VEGF-Ax
Hong Xin et al.
CELL (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Wild-type VHL Clear Cell Renal Cell Carcinomas Are a Distinct Clinical and Histologic Entity: A 10-Year Follow-up
Julien Dagher et al.
EUROPEAN UROLOGY FOCUS (2016)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Programmed Translational Readthrough Generates Antiangiogenic VEGF-Ax
Sandeepa M. Eswarappa et al.
CELL (2014)
Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines
R. Grepin et al.
ONCOGENE (2012)
The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab)
Larry D. Sasich et al.
SAUDI PHARMACEUTICAL JOURNAL (2012)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3
Yunling Xu et al.
JOURNAL OF CELL BIOLOGY (2010)
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment
W. Kimryn Rathmell et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Steven J. Harper et al.
NATURE REVIEWS CANCER (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Autocrine VEGF signaling is required for vascular homeostasis
Sunyoung Lee et al.
CELL (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Angiogenesis in cancer
Naoyo Nishida et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2006)
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen
J Moffat et al.
CELL (2006)
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
M Shibuya et al.
EXPERIMENTAL CELL RESEARCH (2006)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Complete structure of an increasing capillary permeability protein (ICPP) purified from Vipera lebetina venom -: ICPP is angiogenic via vascular endothelial growth factor receptor signaling
A Gasmi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
